Kintara Therapeutics (KTRA)
(Delayed Data from NSDQ)
$0.17 USD
+0.01 (3.94%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $0.17 0.00 (2.16%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Kintara Therapeutics, Inc. [KTRA]
Reports for Purchase
Showing records 1 - 20 ( 49 total )
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer
Provider: Dawson James Securities, Inc.
Analyst: KOLBERT J
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
VAL-083 Fails to Show Benefit vs. SOC in GBM
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
Kintara: Case Studies in GBM Presented at EANO
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
Kintara: Reports Fiscal Fourth Quarter- $1.5M in Cash
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
Kintara: Reports Fiscal Q3 - $2M Expenses $3M in Cash
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
Kintara Therapeutics: Stock is Down Sharply but Not Out
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
1:50 Reverse Split Effective; Receives Orphan Drug Designation for VAL-083 for Treatment of Diffuse Intrinsic Pontine Glioma
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
Kintara Therapeutics Presents Three Posters at the 2022 Society for Neuro-Oncology Annual Meeting - Trading 50:1 Reverse Split
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
Reports 1st Quarter (Sept. YE) - ATM in Place, Focus on VAL83
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
GCAR Trial - We Believe VAL-083 is Likely to Succeed
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
GCAR Trial Continues to Mature VAL-083 Going Strong
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
Lowering to Neutral As the Cash Balance is Tight
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J